Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.42 |
| ▸ | JAK3 | P52333 | 6/20 | 0.42 |
| ▸ | JAK1 | P23458 | 5/20 | 0.41 |
| ▸ | IGF1R | P08069 | 2/20 | 0.40 |
| ▸ | TYK2 | P29597 | 2/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24852539 | 1.00 | JAK2 (0.42) | JAK2JAK3JAK1IGF1RTYK2 | |
| SCHEMBL22097938 | 1.00 | JAK2 (0.42) | JAK2JAK3JAK1IGF1RTYK2 | |
| SCHEMBL30754124 | 1.00 | JAK2 (0.42) | JAK2JAK3JAK1IGF1RTYK2 | |
| SCHEMBL22097988 | 1.00 | JAK2 (0.42) | JAK2JAK3JAK1IGF1RTYK2 | |
| SCHEMBL31557665 | 0.89 | JAK2 (0.44) | JAK2JAK3JAK1IGF1RTYK2 | |
| SCHEMBL24853394 | 0.89 | JAK2 (0.44) | JAK2JAK3JAK1IGF1RTYK2 | |
| SCHEMBL22097704 | 0.89 | JAK3 (0.47) | JAK2JAK3JAK1IGF1RTYK2 | |
| SCHEMBL24853551 | 0.88 | JAK2 (0.45) | JAK2JAK3JAK1IGF1RTYK2 | |
| SCHEMBL31557664 | 0.88 | JAK2 (0.45) | JAK2JAK3JAK1IGF1RTYK2 | |
| SCHEMBL22097843 | 0.86 | JAK2 (0.44) | JAK2JAK3JAK1IGF1RTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115586-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-20230416235-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115586-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | JAK2 3/4885JAK3 2/4885JAK1 1/4885 |
| US-20230416235-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | JAK2 3/4885JAK3 2/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.